On May 11, Scott Gottlieb, M.D., officially became the 23rd commissioner of the U.S. Food and Drug Administration (FDA). Dr. Gottlieb has previous FDA experience, having served as deputy commissioner for medical and scientific affairs, among other positions, during the George W. Bush administration. More recently, he was a venture partner at the world’s largest venture capitalist firm, New Enterprise Associates (NEA), sitting on the boards of several pharmaceutical companies, including GSK, Daiichi Sankyo, and Vertex. He was also a clinical assistant professor and practiced medicine at the New York University (NYU) School of Medicine, and is a cancer survivor (Hodgkin’s lymphoma).
{iframe}https://www.clinicalleader.com/doc/what-can-scott-gottlieb-do-to-advance-the-fda-clinical-trials-0001{/iframe}